logo_large_alt

The Addario Lung Cancer Medical Institute (ALCMI, voiced as “Alchemy”), is an international consortium dedicated to catalyzing and accelerating the discovery, development and delivery of new and more effective treatment options for lung cancer patients.

Latest News
Patients Launch New Study to Shed Light on EGFR-Positive Lung CancersPatients Launch New Study to Shed Light on EGFR-Positive Lung Cancers The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived xenograft (PDX) [...] READ MORE
Addario Lung Cancer Medical Institute Collaborates with Washington University on ctDNA Analysis in Early Stage Lung Cancer Study InVision® ctDNA liquid biopsy platform being explored to help inform the management of patients following surgery of curative intent. The Addario Lung Cancer Medical Institute (ALCMI)… Read More READ MORE
Motivated Patients with ROS1 Cancer Initiate Global Research Study Global collaboration among data scientists, engineers, developers, coders, radiologists and physicians to end the world’s deadliest cancer. The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (NASDAQ: CSBR) and the [...] READ MORE
The Fight of Our Lives: Confronting the Unmet Need in Lung CancerThe Fight of Our Lives: Confronting the Unmet Need in Lung Cancer Medical advancements, over the past year, have been game changing for lung cancer patients. In 1971, President Richard Nixon declared war on cancer, and now, we finally have a war [...] READ MORE
Early Study Results Find High Proportion of Young Lung Cancer Patients With Targetable MutationsEarly Study Results Find High Proportion of Young Lung Cancer Patients With Targetable Mutations The preliminary results showed that 76 percent of study subjects under 40 had druggable mutations. READ MORE
Genomics of Young Lung Cancer and INHERIT Studies Accepted for Presentation at ASCO Two Addario Lung Cancer Medical Institute research studies funded in part by the Bonnie J. Addario Lung Cancer Foundation chosen for presentation at the May/June 2015 American Society of Clinical [...] READ MORE
International Partnership to Address Lung Cancer Epidemic According to a recent study in the Annals of Oncology, lung cancer fatalities are set to overtake breast cancer deaths among European women for the first time this year. It [...] READ MORE
ALCMI Launches Genomics of Young Lung Cancer Study The Addario Lung Cancer Medical Institute (ALCMI) today launched a new study, the Genomics of Young Lung Cancer, to understand why lung cancer occurs in young adults, who quite often [...] READ MORE
Exosome Diagnostics & ALCMI Announce Collaboration on Sequencing Blood CAMBRIDGE, Mass. and LOS ANGELES, Calif., Jan. 9, 2015 – Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced a strategic collaboration with the Addario Lung Cancer [...] READ MORE